GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT02799472
- Locations
- 🇵🇱
GSK Investigational Site, Wroclaw, Poland
A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix-B Kinder
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 302
- Registration Number
- NCT02798952
- Locations
- 🇩🇪
GSK Investigational Site, Neumuenster, Germany
A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT02798978
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: Matched Placebo
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT02798991
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Single and Repeated Dose Escalation Study of GSK2838232
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT02795754
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02794519
- Locations
- 🇪🇸
GSK Investigational Site, Santiago De Compostela. La Coruña., Spain
Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02794467
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use
- Conditions
- Asthma
- Interventions
- Device: ELLIPTA DPIDevice: GSK MDIDevice: AZ MDI
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 324
- Registration Number
- NCT02794480
- Locations
- 🇺🇸
GSK Investigational Site, Waco, Texas, United States
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT02793154
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
- Conditions
- Anaemia
- Interventions
- Drug: 1 to 4 mg tablets of GSK1278863Drug: Epoetin beta pegolDrug: 6 mg GSK1278863 tablet
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 355
- Registration Number
- NCT02791763
- Locations
- 🇯🇵
GSK Investigational Site, Toyama, Japan